The firm's consumer and medical-device group are lagging, but strong results from the pharmaceuticals side should drive earnings throughout this year and into 2015, says Morningstar's Damien Conover .
A handful of health-care names are selling at premiums now, but buying opportunities are surfacing, as well.
Many developed-country health-care firms have deep roots in emerging markets and can be a good way to gain exposure, says Morningstar's Damien Conover .
As the ultimate impact of Obamacare comes into focus, the sector's winners and losers are becoming more apparent.
As the ultimate impact of Obamacare comes into focus, the sector’s winners and losers are becoming more apparent.
Five stats from the market and the stories behind them. This week: content kings, patent cliffs, and 30,000 head to Omaha.
Dave Ricks, head of Lilly's Bio-Medicines group, discusses the pharma giant's competitive advantages with Morningstar's Damien Conover .
Pharmaceutical firms' lower-than-historical valuations and high-margin, patent-protected products are positive signs for investors seeking more yield.
Pharmaceutical firms have adapted to their patent cliffs better than investors expected, and solid pricing power and improving pipelines are allowing them to push through macro headwinds.
Obamacare will benefit some sectors more than others, but poor economy and pricing pressures are the biggest challenges most health-care firms must face.